Based on a licence from Else Marit Inderberg and Sebastien Wälchli’s group at The Section of Cell Therapy at Oslo University Hospital, the company Zelluna Immunotherapy is developing natural killer cells that are steered by T cell receptors. The aim is to offer different forms of targeted immunotherapy treatments that do not have to be individually tailored for each patient. Zelluna Immunotherapy receives NOK 83 million from investors and the Research Council of Norway to continue its work on this new form of cancer immunotherapy.
Published in major journals, first or last author from Oslo University Hospital.
Dynamic brain-to-brain concordance and behavioral mirroring as a mechanism of the patient-clinician interaction
Sci Adv, 6 (43)
Adult Basic Life Support: 2020 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations
Circulation, 142 (16_suppl_1), S41-S91
Colonoscopist Performance and Colorectal Cancer Risk after Adenoma Removal to Stratify Surveillance: two nationwide observational studies
Gastroenterology (in press)